FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
Pharmacists may have noticed greater emergency contraception (EC) use among teens over the last decade, a new US Centers for Disease Control and Prevention (CDC) study suggests.
Only 2 US states require the human papillomavirus (HPV) vaccine for adolescents.
The 2013 American College of Cardiology/American Heart Association guidelines for determining statin eligibility more accurately identify increased risk of cardiovascular events.
Heroin’s popularity is starting to creep into demographic groups that historically had lower rates of use and related deaths.
Latest Issues
$auto_registration$